Ophthalmic Drugs Market – Size, Outlook, Trends and Forecast (2024 – 2032)

Ophthalmic drugs are the type of drugs which are used to treat glaucoma, cataract, diabetic retinopathy, and other ophthalmic disorders. Introduction of novel ocular drug delivery approaches in the market has driven the manufacturers to develop innovative therapeutic approaches for the treatment of ophthalmic disorders. According to the American Academy of Ophthalmology, 11.3 million people in the U.S. suffer from age-related macular degeneration (AMD), while approximately 10% of them are inflicted with wet AMD. Such trends in ophthalmic disorders across the globe contribute to the growth of the market.

Ophthalmic Drugs Market Segments Size & Growth:

Ophthalmic Drugs market size is projected to reach approximately $55 billion by the end of 2024 with a CAGR of close to 6.6% from $30.25 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Availability of new drugs and devices, the Huge demographic shift towards the emerging markets and Increase in the cataract population and so on. However, Increasing healthcare costs and an Economic slowdown in developed markets are thereby hampering the market growth.

Ophthalmic Drugs Market Segments Share:

Ophthalmic Drugs Market is categorised into drugs which comprise of Ophthalmic swelling, Mydriasis drugs, Ophthalmic inflammation drugs, Anti-glaucoma drugs and so on. Among the Drugs, Ophthalmic Infection Drugs market segment dominated the Ophthalmic Drugs market in 2018 with about XX% share. By Geography, North America is expected to dominate the Ophthalmic Drugs market, and the growth in the North America economies is mainly attributed because of higher uptake of advanced novel products and techniques, and the high cost of therapies among all regions. The market in North America is expected to become worth US$13.78 billion by 2024.

Ophthalmic Drugs Market Trends:

• Roche’s ophthalmic research programs are mainly focused on addressing the leading causes of blindness, including neovascular age-related macular degeneration (AMD), diabetic macular edema, glaucoma, geographic atrophy secondary to AMD and other retinal diseases.
• EyeGate Pharmaceuticals, Inc., a clinical-stage, speciality pharmaceutical company with two platform technologies for treating diseases and disorders of the eye, today announced that it had been granted U.S. Patent No. 9,820,935, by the U.S. Patent and Trademark Office (USPTO). The patent, titled “Delivery of corticosteroids through iontophoresis,” covers the iontophoretic delivery of a dexamethasone phosphate formulation to a subject’s eye for the treatment of various conditions, including post-operative inflammation and uveitis.

Ophthalmic Drugs Market Research Report:

• An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
• To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
• Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
• Identifying DROC in the current market and their impact in altering the market dynamics.
• Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
• Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
• The major market players, such as
• Roche
• EyeGate Pharmaceuticals
• Novartis International,Inc.
• CIBA Vision
• Abbott Laboratories